Member Info for AnthonyW

@Prion25. I normally ignore Scinv as he has agenda. I would like to say he is guilty of both being right and wrong. Yes there are autoantibodies to IFN. However, the literature suggests to IFN alpha that about 10% of patients express autoantibodies. There are about 13 types of IFN alpha subtypes. Only 1 IFN beta variety. SNG uses IFN beta currently.

I'm thinking the company with a track record with similar type drugs to VAL201 is Otsuka. Their compound dasatinib is now out of patent. So could be looking at a hopefully new and more specific version. I can't download their pipeline to check if they are interested in women's health.

Val201 mode of action is to block SRC kinase. It won’t be the first drug that targets this receptor in prostate cancer. A drug used in CML (type of blood cancer) got to phase 3 but ultimately proved negative. This is both a positive and negative. The positive is that SRC kinase is seen as a useful target in prostate by interfering with bone mets. Ultimately what PYC will have to show is VAL201 targets the SRC kinase receptor more strongly than dasatinib does. If not then other areas like sepsis and endometriosis will be looked at more. Also it’s likely to be a third line of therapy in prostate cancer will be late down after the patients has exhausted a few other options. But there is still a massive need. https://www.nature.com/articles/nrurol.2013.283

GRACE83-Have you seen AZs cancer pipeline? Its massive. It could be that they are interested in this application more than other areas. There are no real affective treatments for Sepsis. 48k people die in the UK alone from sepsis. It would be a quick trial to run as well compared to most cancer trials. I work in pharma this is just my two pennies worth.

Hi
You may have seen the email that may or may not be real. But the potential of VAL201 in sepsis is a real possibility. For those who don't have a pharma background. VAL201 belongs to the SRC Kinase family. A drug that targets this receptor has also been looked at this in this setting. It is hoped the VAL201 targets this receptor more strongly and if so SEPSIS is a massive unmet need. Possibly much bigger than prostate cancer where there many options.
For those with a scientific interest here is a paper exploring this in more detail.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5936983/

SUPPLY- People are worried about supply for activ 2. What people on here don't realise is the rate limiting step is unlikely to be SNG/CMP. Its likely the labelling that needs to be done for trials. Trials labelling takes a long time due to all the various numbers for tracking and other codes you need. This won't be by SNG it will be by the trial coordinator for ACTIV-2 or pharmaxis for phase 3.

See you next week. Hopefully with lots of good news :-)

EVA-The 80million fund raise was to help production and the phase 3. We have been scaling up production so there will be quite a bit to sell. If ACTIV 2 is positive -The US government will support upscaling manufacture with funds for EUA.

You're the worst deramper ever. Not even subtle.

EVA-I'll happily take your shares off you for £2.50 on positive phase 3. Sounds like a good deal to you.

EVA- You think only a 50% increase on positive phase 3???? This will guarantee FDA, EMA and MHRA access. I would anticipate at least an £8/SP then when orders come in and eventually TO you will see much higher numbers.

Reading your posts I feel you have an ulterior motive.

SHA222 there are lots of cities in America. They only need 100 patients for both arms. In pharma you can limit sites if you're confident that the trial will fill quickly....

TWATCHER-Not suggesting its a UK strategy we have more than enough vaccine on order to vaccinate the population several times over. Maybe an option for the countries where COVAX are aiming to supply. There is not enough vaccine to go around in these countries. We know that UK government policy moves with science. Hence why we have the 12 week interval between AZ doses and the data in the over 65s from Scotland that has pushed the EU to reconsider . Anyway I will leave you to it. I'm not sure engaging on LSE with your type is probably worth the time or energy.

TWATCHER-J&J is a single dose option. The AZ, Moderna and Pfizer trials were two dose approaches in COVID naive population. The question that needs to be answered is do you need two doses in a prior COVID patient who already has measurable levels of antibodies? This is being looked at. I imagine in populations where vaccine rationing is taking place it will be a possible option to look at with hopefully antibody tests to show this.

The antibody test makes sense for those who have had covid they can get away with just one vaccine rather than two doses.

1st March will be when the MPs questions will be answered

Do we know when these questions may be answered?

Do we know if there are more than just the three UK trial centres open for the P3 trial? Clinicaltrials.gov can take its time to update...

Dumbpunter: You're living upto your name. SNG does have FDA fastrack on its PHASE 3 and its part of operation warpspeed for ACTIV-2.

JoeyDiamond-to be fair clinical trial gov can take ages to update the website in particular with recruitment centres

Ghia-Thanks. Shows Hull, Southampton and Birmingham are the current open recruiting centres.